We offer a comprehensive portfolio of treatments for each stage of Relapsing-Remitting Multiple Sclerosis that will help recover the quality of life of patients, by providing them with a sign of confidence.
Multiple Sclerosis is a disease of the central nervous system that affects the brain and spinal cord. Its etiology is autoimmune and has a chronic course that can result in a high degree of disability. This disease is the leading cause of non-traumatic neurologic disability in young adults between the ages of 20 and 40, but it can occur at any age. Proper early detection and therapeutic intervention can significantly improve the course of the disease. It is estimated that 50,000 people in Latin America suffer from multiple sclerosis.
Stendhal is a leading company in Latin America in the development of treatments for Multiple Sclerosis. We have over 7 years of experience in handling products to treat this disease.
To improve the quality of life of patients who suffer from Relapsing-Recurring Multiple Sclerosis, we collaborate with neurologists and healthcare professionals (physical and occupational therapists) to facilitate access to specialized therapies.
We are open to professionals with a high level of initiative, with the capacity to transform uncertainty into opportunities.
© Stendhal International 2022 All Rights Reserved
Stendhal Pharma is property of Específicos Stendhal, S.A. de C.V.